関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|
| 反応物 | 1-Methylpiperazine | HCID 53167 | — |
| 反応物 | N-(5-Bromopyrazin-2-YL)acetamide | HCID 58574049 | — |
| 試薬 | Potassium tert-butoxide | HCID 23665647 | — |
| 触媒 | Tris(1,1-dimethylethyl)phosphine | HCID 83681 | — |
| 触媒 | Bis(dibenzylideneacetone)palladium | HCID 9811564 | — |
| 溶媒 | Dimethylformamide | HCID 6228 | — |
| 生成物 | N-[5-(4-methylpiperazin-1-yl)pyrazin-2-yl]acetamide | HCID 59983941 | 79.51% |
反応手順
1-methylpiperazine (2.318 g, 23.14 mmol), N-(5-bromopyrazin-2-yl)acetamide (1 g, 4.63 mmol), tri-tert-butylphosphine (1.873 g, 9.26 mmol), tris(dibenzylideneacetone)dipalladium (0.085 g, 0.09 mmol) and potassium 2-methylpropan-2-olate (1.039 g, 9.26 mmol) were suspended in DMF (9.26 ml) and sealed into a microwave tube. The reaction was heated to 120 °C for 40 minutes in the microwave reactor and cooled to RT. The mixture was diluted with methanol and acidified with HCl, then the solution was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7M NH3/MeOH and pure fractions were evaporated to dryness to afford N-(5-(4-methylpiperazin-1-yl)pyrazin-2-yl)acetamide (0.866 g, 80 %) as a dark oil. Used without further purification.
情報源と証拠
| 出典データセット | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-96727602adb24b28af9c737e24f7315c |
|---|
| 出典メモ | 750 AstraZeneca ELN dataset |
|---|